secwatch / observer
TRDA Entrada Therapeutics, Inc.
CIK 0001689375 49 ready 8-Ks latest June 10, 2026, 4:06 PM ET RSS · JSON
Activity: QUIET 0 filings / 30d vs 1 baseline
Ready 8-Ks 49
Latest filing June 10, 2026, 4:06 PM ET
Top materiality 0.90
Event mix other_material ×17 · earnings ×17 · leadership ×6
Sentiment 21 pos · 5 neg · 23 neu
Latest earnings reported 2025-FY
Executive change recent →

Recent 8-K filings for TRDA

Highest-materiality recent filing

Entrada licenses DM1 program to Vertex for $224M upfront, $26M equity, up to $485M milestones

December 8, 2022, 6:59 PM ET M&A materiality 0.90 positive item 1.01item 3.02item 7.01item 9.01 ◈ Material Agreements ×2

Read filing →

Executive changes

Appointed

Maha Radhakrishnan

Class III director
TRDA · Entrada Therapeutics, Inc.
Effective
2025-06-01
Filed
June 3, 2025, 7:59 PM ET
On May 30, 2025, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) expanded the size of the Board from six to seven directors and appointed Maha Radhakrishnan, M.D. to the Board as a Class III director, to serve until the Company’s annual meeting of stockholders to be held in 2027 or until her successor is duly elected and qualified, in each case effective as of June 1, 2025.
Role change

Nathan J. Dowden

President and Chief Operating Officer
TRDA · Entrada Therapeutics, Inc.
Effective
2024-01-01
Filed
January 3, 2024, 6:59 PM ET
appointed Nathan J. Dowden, the Company’s Chief Operating Officer, to serve as the Company’s President, effective as of January 1, 2024
Departed

John F. Crowley

member of the Board of Directors
TRDA · Entrada Therapeutics, Inc.
Effective
2023-12-05
Filed
December 6, 2023, 6:59 PM ET
On December 5, 2023, John F. Crowley, a member of the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board, including the Audit Committee of the Board (the “Audit Committee”), on which he serves as a member, and the Compensation Committee of the Board (the “Compensation Committee”), on which he serves as the Chair, effective December 5, 2023.
Appointed

Gina Chapman

Class III director
TRDA · Entrada Therapeutics, Inc.
Effective
2023-09-01
Filed
August 10, 2023, 7:59 PM ET
On August 4, 2023, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) appointed Gina Chapman to the Board as a Class III director, effective September 1, 2023
Departed

Todd Foley

member of the Board of Directors
TRDA · Entrada Therapeutics, Inc.
Effective
2023-06-07
Filed
June 8, 2023, 7:59 PM ET
On June 7, 2023, Todd Foley notified Entrada Therapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”), effective as of June 7, 2023.
Appointed

Bernhardt Zeiher

Director
TRDA · Entrada Therapeutics, Inc.
Effective
2023-04-04
Filed
April 4, 2023, 7:59 PM ET
Effective as of April 4, 2023, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) expanded the size of the Board from seven to eight directors and appointed Bernhardt Zeiher, M.D. to the Board as a Class II director, to serve until the annual meeting of stockholders held in 2023 or until his successor is duly elected and qualified.

Earnings & guidance

2025-FY EPS reported -$3.47 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event other_material

21 positive 5 negative 23 neutral

source · TRDA on sec.gov